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was to identify existing deﬁ nitions of innovation, values inherent in innovation initia-
tives, and important considerations for the development of policies to promote innova-
tion of health technologies. METHODS: A literature search of bibliographic databases 
including PubMed, EMBASE, Web of Science, Centre for Reviews and Dissemination 
databases, National Library of Medicine Gateway, EconLit and the New York 
Academy of Medicine Grey Literature collection was conducted for the period January 
2005 to April 2010. The search terms were intended to capture concepts of “innova-
tion” and “policy” in the health technology (drugs, devices, etc,) sector. Two research-
ers reviewed titles and abstracts of over 4500 references identiﬁ ed; 200 papers were 
retrieved for full review. Key components of innovation were extracted and summa-
rized in tabular form to identify trends and emerging themes. RESULTS: System 
disrupting, development of relationships and improvement on current practice are 
examples of components of, or criteria for deﬁ ning, health technology innovation. 
Thematic concepts that emerged during the review include innovative health technol-
ogy as a novelty and as a mechanism for achieving some beneﬁ t or good (broadly-
deﬁ ned) at various levels of the health system. CONCLUSIONS: Based on the variety 
of deﬁ nitions in the literature, lack of a common understanding of innovation may 
result in policy incoherence. The use of a consistent and unambiguous deﬁ nition 
provides a solid framework from which to develop policy that is measurable, meaning-
ful and, therefore, has a greater chance of being effective.
PHP12
PHYSICIANS VIEWS ON BIOMEDICAL TECHNOLOGY IN GREECE
Tsiantou V1, Skroumpelos A1, Mylona K1, Athanasakis K1, Konstantinopoulos O2, 
Kyriopoulos J1
1National School of Public Health, Athens, Greece; 2Sotiria Hospital, Athens, Greece
OBJECTIVES: Given the signiﬁ cant impact of biomedical technology on health, the 
present study aims at identifying the accessibility to certain biomedical technologies 
and factors affecting its use and diffusion, in Greece. METHODS: A strictly structured 
questionnaire was designed and sent to a sample of 388 internists and GPs over 50 
years old, stratiﬁ ed by geographical area and employment sector. Participants were 
asked a) to evaluate on a 1 to 10 point scale patient access to selected biomedical 
technologies and the degree to which selected factors affect their decision to use the 
above interventions and b) to rank certain factors effect on the diffusion of biomedical 
technologies. RESULTS: The response rate was 76%. The statistical analysis revealed 
that the most accessible biomedical technologies were ultrasonography (9.4), PSA 
(9.38), cardiac enzymes (8.99), MRI and CT (8.86), and mammography (8.83). The 
most important factors affecting participants’ decision to use a technology were the 
treatment outcome (9.23), the disease severity (9.11) and the appropriateness of the 
technology for each condition (8.27) while factors such as health system and patient 
cost were proved less inﬂ uential. 68.1% of participants claimed delays in the diffusion 
of biomedical technology in Greece, identifying as major barriers economic and spe-
cialized human resources deﬁ ciencies. CONCLUSIONS: Based on our results, higher 
access was observed to technologies related to neoplasms and cardiovascular diseases, 
which represent the main causes of morbidity and mortality in Greece. Furthermore, 
our ﬁ ndings support the view that when it comes to use a technology physicians are 
mostly concerned with the clinical effectiveness of an intervention and less with its 
impact on health care expenditures. Finally, the major diffusion barriers identiﬁ ed in 
this study show a suboptimal resource allocation practice, stressing the need for 
measures to be taken in this direction in order to enhance diffusion of biomedical 
technologies in Greece.
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OBJECTIVES: Transparency Directive (TD) of the European Union aims to ensure 
the transparency of procedures for the pricing and reimbursement of medicinal prod-
ucts by Member States. TD proposes strict timelines for the pricing and reimbursement 
process and indicates the necessity of objective and veriﬁ able criteria for decisions and 
the availability of remedies for negative decisions. Our objective was to compare the 
routine process of pharmaceutical pricing and reimbursement with the TD in Hungary. 
METHODS: We analyzed ofﬁ cial resolutions of 29 pricing and reimbursement sub-
missions by the National Health Insurance Fund (NHIF) between January and June 
2008. In 14 cases the NHIF granted reimbursement, in 15 cases the reimbursement 
claim was rejected. We calculated the time period between the submission of the 
reimbursement dossier and the ofﬁ cial decision. We assessed the consistency of apply-
ing objective and veriﬁ able criteria in positive or negative decisions. RESULTS: The 
average time period for pricing and reimbursement procedure was 172 days (min: 43 
days; max: 534 days). We could not justify the consistency of employing objective and 
veriﬁ able criteria in the pricing and reimbursement resolutions of innovative pharma-
ceuticals. CONCLUSIONS: The pharmaceutical pricing and reimbursement process 
in Hungary is neither transparent nor predictable. There are several open pricing and 
reimbursement submissions without resolution for long period. Although we could 
analyze only cases with resolution, the time period for pricing and reimbursment 
decision was still longer in several cases than 90 + 90 days recommended by TD. The 
appropriate use of scarce public health care resources could not be justiﬁ ed in case of 
positive decisions and there is no remedy for negative reimbursement decisions. TD 
has been implemented only partially in Hungary.
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OBJECTIVES: The Joint Committee for New Drugs Evaluation (JCNDE) was estab-
lished in 2003 to improve efﬁ ciency in drug evaluation in Spain. Five Regional Drug 
Evaluation Centres are part of it and have common Standard Operating Procedures 
(SOPs) which are regularly updated and improved. The objective of this study was to 
analyze the drugs innovation degree scores assigned by the JCNDE and timing between 
the new drug commercialization and the JCNDE evaluation. METHODS: The JCNDE 
SOPs deﬁ ne a stepwise procedure with 4 key criteria for new drug innovation ratings: 
efﬁ cacy, safety, convenience and drug cost. The drug innovation scores range from 0 
(insufﬁ cient experience with the drug) to 4 (relevant therapeutic improvement). The 
drug evaluation results were gathered from JCNDE reports and from the Regional 
Drug evaluation centre reports. The time period analyzed was from 2004 to 2009. 
RESULTS: Ninety drug evaluations were held, considering 86 different drugs and 11 
evaluations for a new drug indication for the same drug. Seventy-eight (87%) of the 
evaluations were negative (scores 0–1), not ﬁ nding any 0 in the last 2 years of the 
study. Ten and 2 evaluations were scored as 2 and 3 respectively. None of the drugs 
assessed were considered a relevant therapeutic improvement compared to the existing 
options. Five drugs not reimbursed were evaluated. Median time since commercializa-
tion to evaluation was 6 months (IQR: 2–11 months) and 32 drug evaluations were 
held before up to a maximum of 3 months after commercialization. CONCLUSIONS: 
The JCNDE has been an efﬁ cient instrument to develop new drug assessments in the 
Primary Care setting for the Regional Health Systems in Spain. Most of the assess-
ments held have been negative. At present, health-economics arguments are basically 
focused on the daily treatment cost comparisons. About 1/3 of the evaluations are 
started before drug commercialization.
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OBJECTIVES: The Spanish Joint Committee for New Drugs Evaluation (JCNDE) was 
created in 2003 and is formed by 5 Regional Drug Evaluation Centres. JCNDE has 
common Standard Operating Procedures (SOPs) to unify drug assessments and where 
the comparators availability is a key issue. Each individual Drug Evaluation Centre 
has its own new drug therapeutic bulletin to spread information between their health 
professionals. The objective of this study was to quantify the uniformity degree 
through the drug bulletins and the degree of heterogeneity reﬂ ected in the drug costs. 
METHODS: New drug therapeutic bulletins of the 5 members of the JCNDE were 
reviewed between 2006 and 2009. Each drug assessed by the JCNDE was tracked to 
identify which members reported it in their bulletins. Comparative drugs included in 
the bulletins were also registered to ﬁ nd potential heterogeneity amongst the JCNDE 
members. Daily/monthly treatment costs described were included in the study data-
base. RESULTS: Fifty-seven drug evaluations were recorded, forty (70%) were pub-
lished by at least 3 members of the JCNDE, and only 12 were published by all of 
them. Andalusia, Basque Country and Catalonia are the most active members, with 
12–14 new drugs published per year. In all the bulletins were identiﬁ ed some differ-
ences in the comparators used for each new drug assessed. Andalusia and Catalonia 
tend to include more comparators. The highest level of heterogeneity is observed in 
drugs of diabetes treatment. Most of the drug costs reported were very similar. Only 
one disagrement between the JCNDE was identiﬁ ed in the drug innovation rating. 
CONCLUSIONS: JCNDE has made advances to unify drug assessment in Spain. 
Nevertheless, health-economics arguments are still focused on drug treatment cost 
comparisons. The comparators found in the drug bulletins are slightly different 
amongst the regions. Future SOPs version ought to improve these two weak points.
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OBJECTIVES: To promote the research and development of drugs for rare diseases, 
like other countries, orphan designations have been granted to pharmaceuticals in 
Japan since 1993. We investigated the accessibility of orphan drugs in Japan by 
comparing the accessibility of orphan designated and marketing authorised drugs in 
the EU and the US. METHODS: The present study used the data available until the 
November 30, 2009 from the European Medicines Agency, US Food and Drug 
Administration and National Institute of Biomedical Innovation. The International 
Nonproprietary Names (INNs) were used for comparing authorised orphan desig-
nated drugs in Japan, the EU and the US. RESULTS: A total of 228 products had 
been granted orphan designation, of which 142 (62%) obtained marketing authoriza-
tion in Japan, which is equivalent to 122 in INNs. Meanwhile, the number of autho-
rised orphan-designated medicines in INNs in the EU and the US was 57 and 198, 
respectively. Of the total 287 authorised orphan-designated pharmaceuticals in INNs 
in these 3 regions, 165 were inaccessible in Japan through the orphan designation 
system. Among such drugs, 25 (15%) were authorised orphan designated in both the 
EU and the US, 15 (9%) were authorised orphan designated in the EU alone and 125 
(76%) were authorised orphan designated in the US alone. CONCLUSIONS: We 
